Latest Immunosuppressive drug Stories
U.S. researchers say the use of modern immunosuppressive drugs eliminates the need for steroid therapy as early as seven days following a kidney transplant. Dr.
MOUNT LAUREL, N.J., Sept. 18 /PRNewswire/ -- Composite Tissue Transplantation (CTT) represents a new frontier in the field of transplantation. Since 1998, surgeons worldwide have performed about 50 composite tissue transplantations, including faces, hands, larynx and abdominal walls.
DOR BioPharma, Inc.
COLUMBIA, Md., Aug.
GAITHERSBURG, Md., Aug. 12 /PRNewswire/ -- MedImmune today announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus).
PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus).
WASHINGTON, July 30 /PRNewswire-FirstCall/ -- The ability of blood tests to precisely measure very low doses of anti-rejection drugs in kidney transplant patients may make a significant difference in assuring long-term viability and survival, according to research presented today at the American Association for Clinical Chemistry (AACC) annual meeting.
SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye.
Chinese scientists say a treatment using several drugs targeting various parts of the immune system helps patients with severe lupus involving the kidneys.
TORONTO, June 1 /PRNewswire/ -- The final results of the Spare the Nephron (STN) study, a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil), showed the CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI).
- An armed gangster.